Olomorasib receives FDA Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer August 5, 2026
Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure August 5, 2026
IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers August 5, 2026
FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer Announced August 5, 2026
Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC August 5, 2026
RYBREVANT FASPRO (amivantamab & hyaluronidase-lpuj) receives FDA Priority Review for EGFR- & MET-targeted subQ treatment for advanced head and neck cancer August 5, 2026
Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Gen ADC Manufacturing Technologies August 5, 2026
CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics August 5, 2026
Final subject received last dose of Ampligen (rintatolimod) in Ph 2 DURIPANC trial of Ampligen + Imfinzi for the treatment of metastatic pancreatic cancer August 5, 2026
Strong Enrollment Momentum Reported in Ph 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer August 5, 2026
FAILED TRIAL: Ph 3 XPORT-EC-042 Trial of Selinexor in Endometrial Cancer Did Not Meet the Primary Endpoint of PFS improvement August 5, 2026
MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients August 5, 2026
IND Application for Ph 1b/2 Opamtistomig Combo in Metastatic Colorectal Cancer Approved August 5, 2026
FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) August 5, 2026
FDA RMAT Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as 1L Consolidation Therapy for LBCL August 5, 2026
Supplemental NDA submission for Selinexor Plus Ruxolitinib in Myelofibrosis Planned Under Accelerated Approval Pathway August 5, 2026
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the NCCN Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer August 5, 2026
